Navigation Links
Eurand's Zentase Effective in Treating Exocrine Pancreatic,Insufficiency, Studies Show

n contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to our plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potentially", "could", "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as a part of our NDA filing. Forward- looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward- looking statements.

    (1) Littlewood, James M., and Susan P. Wolfe. "Control of Malabsorption

        in Cystic Fibrosis." Paediatric Drugs (2000; 2 : 205-22)

    (2) Guidance for Industry Exocrine Pancreatic Insufficiency Drug Products

        - Submitting NDAs. U.S. Department of Health and Human Services, Food

        and Drug Administration (FDA), Center for Drug Evaluation and Research

        (CDER), April 2006

    (3) United States Pharmacopeia (USP) standards for pancreatic enzyme

        products (will get full refer
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Eurand to Present Zentase Phase III Data
2. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
3. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
8. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
9. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
10. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
11. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
Post Your Comments:
(Date:9/18/2014)... and CHESTERBROOK, Pa. , Sept. 18, ... VVUS ) and Auxilium Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has approved a supplemental new drug application ... only FDA-approved erectile dysfunction (ED) medication indicated to be taken ... STENDRA is a prescription medication in a class of ...
(Date:9/17/2014)... , Sept. 17, 2014 BRIC Gynecological ... GlobalData,s new report, "BRIC Gynecological ... data on the BRIC Gynecological Devices market. The ... volume (in units) and average prices (in US ... (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices ...
(Date:9/17/2014)... MONICA, Calif. , Sept. 17, 2014  Dr. ... is at the White House today for National Recovery ... 46 that consumer advocates released today. Consumer advocates were ... woman who spoke out after losing her fiancée ... discovering that the doctor had a history of crack ...
Breaking Medicine Technology:VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3
... 18, 2011 Adeona Pharmaceuticals, Inc. (Amex: ... central nervous system diseases, announced today that it will ... 8, 2011 from 3:00-5:00 P.M. (EST) at the Kensington ... Arbor, Adeona,s management team welcomes shareholders, potential investors and ...
... Companion Animal Health has launched its second product in ... + milbemycin oxime), a broad-spectrum parasiticide that kills fleas ... flea infestations, the prevention of heartworm disease and the ... infections in dogs and puppies 8 weeks and older, ...
Cached Medicine Technology:Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease 2Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease 3Elanco Launches Broad-Spectrum Canine Parasiticide 2Elanco Launches Broad-Spectrum Canine Parasiticide 3Elanco Launches Broad-Spectrum Canine Parasiticide 4
(Date:9/18/2014)... 2014 With the development of ... of adjusting human body physiology, preventing diseases, promoting ... with a variety of specific populations. In 2013, ... reached RMB187.4 billion, up 12.0% year on year, ... View Full Report at http://www.marketresearchreports.biz/analysis/223449 , ...
(Date:9/18/2014)... MA (PRWEB) September 18, 2014 ... its team and surgeon partners in Less Exposure ... joining SpineFrontier, Tamara authored an extensive education curriculum ... a Masters in Science in Organizational Leadership, and ... industries for eleven years. Bringing her to the ...
(Date:9/18/2014)... Dr. Suzaunna Clark, Psychologist, Life Coach ... beauty has to be seen to be believed and ... order to be used. Together, both lead to hearts ... how to do both. , Dr. Clark ... Healing Hearts system, which provides professional guidance on dealing ...
(Date:9/18/2014)... Specialty Teleradiology LLC, a provider of teleradiology services ... achieved Meaningful Use and increased operational efficiency since ... developed by RamSoft. , Before implementing PowerServer ... PACS and a RIS that was built in-house. ... oncology to other subspecialties, they needed a robust, ...
(Date:9/18/2014)... 2014 N-Zyme Scientifics LLC achieved a ... first product a mere 8 months after company startup. ... performance glycan release enzyme used in the “Biologics” industry ... basis for tissue pathology on Mass Spec devices. PRIME™ ... the North American market (PNGase F PRIMETM). N-Zyme ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 3Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 2Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 3Health News:N-Zyme Scientifics Announces Successful Product Launch 2
... latest research unhealthy ways of expressing anger are associated ... //expressing anger." According to past research, stress can also ... not practice healthy anger or stress management may be ... adolescents, ages 14 to 17, for three years. In ...
... New research shows one virus could help fight another. ... // hepatitis G , may hold a key ... ,Researchers analyzed results from the Multicenter Acquired ... large group of HIV-infected men in the United States ...
... put a woman at increased risk of developing asthma, report ... obstructive pulmonary disease (COPD) risk. ,The incidence of both ... 5 percent to 8 percent of Americans have asthma, and ... since 1982. Since the prevalence of asthma tends to change ...
... lose significant bone mass in the first year after the ... their bodies from rejecting the new organ. The bone loss ... of fractures among this group ranges from 22 percent to ... treatment, but which drugs work best in this situation is ...
... is showing promising results.For the past decade, researchers // ... immunotoxin is bioengineered and consists of only the most ... commonly used to fight leukemia. One of those immunotoxins, ... study. ,Researchers say in a phase I study, ...
... estimates that 40 million people are infected with the ... In some African countries, 40 percent of pregnant women ... caught HIV. ,In impoverished areas where the ... one-time treatment for HIV-infected pregnant women to keep them ...
Cached Medicine News:Health News:Drug to stop HIV spread to babies may Indirectly harm The Mother 2
... Alliance Catheter Delivery System (CDS) ... stabilization of the Aescula LV ... has a patented coronary sinus ... and easy access to the ...
... PCS2 system is Haemonetics ... collection of plasma and ... the collection of "jumbo" ... platelet-poor plasma with optional ...
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... Pipette* provides quick, convenient, repetitive dispensing ... Combitips have a polyethylene plunger and ... for use with most reagents. ... Five separate volumes can be selected ...
Medicine Products: